KR20040065223A - 크산틴 옥시다제 저해제 - Google Patents
크산틴 옥시다제 저해제 Download PDFInfo
- Publication number
- KR20040065223A KR20040065223A KR10-2004-7007333A KR20047007333A KR20040065223A KR 20040065223 A KR20040065223 A KR 20040065223A KR 20047007333 A KR20047007333 A KR 20047007333A KR 20040065223 A KR20040065223 A KR 20040065223A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- carbon atoms
- atom
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
실시예 No. | IC50(nM) |
실시예 1-A | 63.2 |
실시예 1-B | 44.8 |
실시예 2 | 11.1 |
실시예 6 | 75.9 |
실시예 7 | 102.0 |
실시예 8 | 18.6 |
실시예 9 | 58.4 |
실시예 10 | 50.0 |
실시예 11 | 22.3 |
실시예 12 | 161.3 |
알로퓨리놀 | 542.1 |
실시예 No. | 저해율(%) |
실시예 1-B | 60.7 |
실시예 6 | 63.8 |
실시예 8 | 56.8 |
실시예 10 | 56.1 |
실시예 11 | 51.4 |
Claims (12)
- 하기 화학식 (Ⅰ)로 나타내는 화합물 또는 그 염:[화학식 I](식 중 R1은 탄소수 1∼8 의 알킬기, 1∼3 개의 할로겐원자로 치환된 탄소수 1∼8 의 알킬기, OR4, CO2R5또는 S(O)nR6을 나타내고, 여기에서 R4는 수소원자 또는 치환기로서 할로겐원자, 수산기, 니트로기 혹은 시아노기에서 선택되는 기 혹은 원자를 가지고 있을 수 있는 탄소수 1∼8 의 알킬기, 아르알킬기(아릴 부분의 탄소수는 6∼10 이고, 알킬 부분의 탄소수 1∼4), 탄소수 2∼9 의 알킬카르보닐기, 아릴카르보닐기(아릴 부분의 탄소수는 6∼10), 아르알킬카르보닐기(아릴 부분의 탄소수는 6∼10 이고, 알킬카르보닐 부분의 탄소수는 2∼5) 혹은 탄소수 6∼10 의 아릴기를 나타내고, R5및 R6은 수소원자 또는 치환기로서 할로겐원자, 수산기, 니트로기, 시아노기 혹은 아미노기에서 선택되는 기 혹은 원자를 가지고 있을 수 있는 탄소수 1∼8 의 알킬기, 아르알킬기(아릴 부분의 탄소수는 6∼10 이고, 알킬 부분의 탄소수 1∼4), 혹은 탄소수 6∼10 의 아릴기를 나타내고, n 은 0∼2 의 정수를나타내고,R2는 수소원자, 할로겐원자, 니트로기, 시아노기, 포르밀기, 탄소수 1∼8 의 알킬기, 1∼3 개의 할로겐원자로 치환된 탄소수 1∼8 의 알킬기 또는 CO2R7을 나타내고, 여기에서 R7은 상기한 R5와 동일한 것을 나타내고,R3은 수소원자, 할로겐원자, 수산기, 아미노기, CO2R8, PO3H, PO(OH)(OR9), S(O)mR10또는 치환기로서 할로겐원자, 수산기, 니트로기, 시아노기 혹은 아미노기에서 선택되는 기 혹은 원자를 가지고 있을 수 있는 탄소수 1∼8 의 알킬기 혹은 알킬아미노카르보닐기, (알킬기의 탄소수는 1∼8)를 나타내고, 여기에서 R8, R9및 R10은 상기한 R5와 동일한 것을 나타내며, m 은 상기 n 과 동일한 것을 나타내고,X 는 NR11, 산소원자, 또는 황원자를 나타내고, 여기에서 R11은 수소원자 또는 치환기로서 할로겐원자, 수산기, 니트로기, 시아노기 혹은 아미노기에서 선택되는 기 혹은 원자를 가지고 있을 수 있는 탄소수 1∼8 의 알킬기를 나타내고, 그리고 Y 및 Z 는 CR12또는 질소원자를 나타내고, 여기에서 R12는 상기한 R3과 동일한 것을 나타낸다.)
- 제 1 항에 있어서, R1이 OR4인 화합물 또는 그 염.
- 제 1 항에 있어서, R1이 탄소수 1∼5 의 알콕시기인 화합물 또는 그 염.
- 제 1 항에 있어서, R1이 이소부톡시기인 화합물 또는 그 염.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서, R2가 니트로기, 시아노기, 할로겐원자 또는 카르복실기인 화합물 또는 그 염.
- 제 1 항 내지 제 4 항 중 어느 한 항에 있어서, R2가 니트로기 또는 시아노기인 화합물 또는 그 염.
- 제 1 항 내지 제 6 항 중 어느 한 항에 있어서, R3이 수소원자, 아미노기, 수산기, 할로겐원자 또는 카르복실기인 화합물 또는 그 염.
- 제 1 항 내지 제 7 항 중 어느 한 항에 있어서, X 가 NH 또는 산소원자이고, Y 및 Z 가 모두 질소원자인 화합물 또는 그 염.
- 제 1 항 내지 제 7 항 중 어느 한 항에 있어서, X 가 황원자, 산소원자 또는 NH 이고, Y 가 CH, C-OH 또는 C-CO2H 이고, Z 가 CH 인 화합물 또는 그 염.
- 제 1 항 내지 제 7 항 중 어느 한 항에 있어서, X 가 NH 이고, Y 및 Z 중 어느 하나가 질소원자이고, 나머지가 CH 인 화합물 또는 그 염.
- 제 1 항 내지 제 10 항 중 어느 한 항에 기재된 화합물 또는 그 염을 유효성분으로서 함유하는 크산틴 옥시다제 저해제.
- 제 1 항 내지 제 10 항 중 어느 한 항에 기재된 화합물 또는 그 염을 유효성분으로서 함유하는 고뇨산 혈증 치료제.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001352340 | 2001-11-16 | ||
JPJP-P-2001-00352340 | 2001-11-16 | ||
PCT/JP2002/011893 WO2003042185A1 (fr) | 2001-11-16 | 2002-11-14 | Inhibiteurs de la xanthine oxydase |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040065223A true KR20040065223A (ko) | 2004-07-21 |
KR100919147B1 KR100919147B1 (ko) | 2009-09-25 |
Family
ID=19164532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047007333A KR100919147B1 (ko) | 2001-11-16 | 2002-11-14 | 크산틴 옥시다제 저해제 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7253154B2 (ko) |
EP (1) | EP1452528B1 (ko) |
JP (2) | JP4634037B2 (ko) |
KR (1) | KR100919147B1 (ko) |
CN (2) | CN101092400A (ko) |
AT (1) | ATE404541T1 (ko) |
DE (1) | DE60228316D1 (ko) |
DK (1) | DK1452528T3 (ko) |
ES (1) | ES2309213T3 (ko) |
PT (1) | PT1452528E (ko) |
WO (1) | WO2003042185A1 (ko) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1587821T1 (sl) * | 2002-12-19 | 2009-02-28 | Scripps Research Inst | Sestavki in postopki za stabiliziranje transtiretina in zaviranje napaäśnega zvijanja transtiretina |
WO2005105803A2 (en) * | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
DK1757610T3 (da) * | 2004-06-14 | 2011-08-01 | Nippon Chemiphar Co | Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor |
KR101191071B1 (ko) | 2004-06-14 | 2012-10-15 | 닛뽕 케미파 가부시키가이샤 | 축합 피리미딘 유도체 및 크산틴 옥시다제 저해제 |
US8557831B2 (en) * | 2004-07-21 | 2013-10-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
CN101248074A (zh) * | 2005-07-01 | 2008-08-20 | 日本化学医药株式会社 | 黄嘌呤氧化酶抑制剂 |
EP3219319A1 (en) * | 2006-06-22 | 2017-09-20 | Nippon Chemiphar Co., Ltd. | Agent for overcoming resistance to anti-cancer agent |
EP2074223A4 (en) * | 2006-09-15 | 2010-03-10 | Foldrx Pharmaceuticals Inc | TEST PROCEDURE FOR THE DETECTION OF PROTEINS IN THE NATIVE CONDITION AND FOR THE IDENTIFICATION OF THE STABILITY OF PROTEINS IN THE NATIVE CONDITION MODULATING COMPOUNDS |
WO2008126899A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | 5員環へテロ環誘導体及びその医薬用途 |
EP2165705A1 (en) | 2008-09-18 | 2010-03-24 | Centre National de la Recherche Scientifique (CNRS) | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
JP5673008B2 (ja) | 2010-08-11 | 2015-02-18 | ソニー株式会社 | 画像処理装置、立体画像表示装置および立体画像表示システム、ならびに立体画像表示装置の視差ずれ検出方法および立体画像表示装置の製造方法 |
CN102095825B (zh) * | 2010-12-08 | 2014-07-23 | 中国科学院长春应用化学研究所 | 超高效液相色谱和质谱联用筛选黄嘌呤氧化酶抑制剂的方法 |
RU2586330C2 (ru) | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Твердые формы ингибитора диссоциации транстиретина |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US9186361B2 (en) | 2013-03-15 | 2015-11-17 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
LT3083627T (lt) | 2013-12-19 | 2018-12-27 | Novartis Ag | [1,2,4]triazolo[1,5-a]pirimidino dariniai kaip protozoano proteasomos inhibitoriai, skirti parazitinių ligų tokių kaip leišmaniozė, gydymui |
JP2017048116A (ja) * | 2014-01-10 | 2017-03-09 | 国立研究開発法人国立国際医療研究センター | 肺高血圧症治療薬 |
WO2016136727A1 (ja) * | 2015-02-24 | 2016-09-01 | 国立大学法人鳥取大学 | 認知症の予防及び/又は治療のための医薬 |
CN106146533B (zh) * | 2016-07-14 | 2018-04-03 | 华润赛科药业有限责任公司 | 含硫杂环羧酸类衍生物、其制备方法和应用 |
WO2020009374A1 (ko) * | 2018-07-04 | 2020-01-09 | 고려대학교 세종산학협력단 | 4-치환 옥사졸로퀴놀리논 유도체, 약학적으로 허용되는 이의 염인 화합물 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물 |
CN110283137A (zh) * | 2019-06-13 | 2019-09-27 | 爱斯特(成都)生物制药股份有限公司 | 一种2-(4-溴苯基)-1,3-苯并恶唑的制备方法 |
CN111620833A (zh) * | 2020-06-05 | 2020-09-04 | 青岛伯川特聚科技有限公司 | 一种2-苯基苯并噁唑类化合物的制备方法 |
CN113004188B (zh) * | 2021-03-16 | 2022-09-20 | 沈阳药科大学 | 一种吲哚衍生物及制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
DE2927988A1 (de) * | 1979-07-11 | 1981-02-05 | Thomae Gmbh Dr K | Neue 8-phenyl-purine, deren herstellung und deren verwendung als arzneimittel |
ZA832938B (en) | 1982-05-03 | 1984-12-24 | Lilly Co Eli | 2-phenylimidazo(4,5-c)pyridines |
JPS62246581A (ja) * | 1986-04-17 | 1987-10-27 | Chugai Pharmaceut Co Ltd | フロベンゾオキサゾ−ル誘導体 |
NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
JPH03258770A (ja) | 1990-03-08 | 1991-11-19 | Tanabe Seiyaku Co Ltd | ベンズアゾール誘導体、その製法及びその合成中間体 |
JP3176073B2 (ja) * | 1990-06-19 | 2001-06-11 | キヤノン株式会社 | 液晶素子 |
BR0111564A (pt) | 2000-06-14 | 2003-04-29 | Warner Lambert Co | Indol e benzimidazol como inibidores da 15-lipoxigenase |
JP2004503553A (ja) * | 2000-06-14 | 2004-02-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 6,5−縮合二環式複素環 |
GB0205256D0 (en) | 2002-03-06 | 2002-04-17 | Oxford Glycosciences Uk Ltd | Novel compounds |
-
2002
- 2002-11-14 CN CNA2007101369545A patent/CN101092400A/zh active Pending
- 2002-11-14 JP JP2003544021A patent/JP4634037B2/ja not_active Expired - Fee Related
- 2002-11-14 DK DK02780099T patent/DK1452528T3/da active
- 2002-11-14 AT AT02780099T patent/ATE404541T1/de active
- 2002-11-14 KR KR1020047007333A patent/KR100919147B1/ko active IP Right Grant
- 2002-11-14 EP EP02780099A patent/EP1452528B1/en not_active Expired - Lifetime
- 2002-11-14 US US10/495,844 patent/US7253154B2/en not_active Expired - Lifetime
- 2002-11-14 DE DE60228316T patent/DE60228316D1/de not_active Expired - Lifetime
- 2002-11-14 CN CNB028272056A patent/CN100338040C/zh not_active Expired - Fee Related
- 2002-11-14 ES ES02780099T patent/ES2309213T3/es not_active Expired - Lifetime
- 2002-11-14 PT PT02780099T patent/PT1452528E/pt unknown
- 2002-11-14 WO PCT/JP2002/011893 patent/WO2003042185A1/ja active IP Right Grant
-
2007
- 2007-07-27 US US11/829,286 patent/US20070265283A1/en not_active Abandoned
-
2010
- 2010-04-06 JP JP2010088128A patent/JP5297414B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7253154B2 (en) | 2007-08-07 |
JP4634037B2 (ja) | 2011-02-16 |
ATE404541T1 (de) | 2008-08-15 |
JPWO2003042185A1 (ja) | 2005-03-10 |
CN1615299A (zh) | 2005-05-11 |
US20050090472A1 (en) | 2005-04-28 |
EP1452528A4 (en) | 2005-11-16 |
EP1452528A1 (en) | 2004-09-01 |
EP1452528B1 (en) | 2008-08-13 |
DK1452528T3 (da) | 2008-11-10 |
US20070265283A1 (en) | 2007-11-15 |
ES2309213T3 (es) | 2008-12-16 |
DE60228316D1 (en) | 2008-09-25 |
WO2003042185A1 (fr) | 2003-05-22 |
JP2010180232A (ja) | 2010-08-19 |
PT1452528E (pt) | 2008-10-14 |
CN100338040C (zh) | 2007-09-19 |
KR100919147B1 (ko) | 2009-09-25 |
CN101092400A (zh) | 2007-12-26 |
JP5297414B2 (ja) | 2013-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100919147B1 (ko) | 크산틴 옥시다제 저해제 | |
EP0513379B1 (en) | 2-arylthiazole derivative and pharmaceutical composition containing the same | |
JP4914210B2 (ja) | 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤 | |
EP2383262B1 (en) | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | |
JPS6032638B2 (ja) | 3−アミノピラゾロ〔3,4−d〕ピリミジン誘導体 | |
KR20150080423A (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
US20040198768A1 (en) | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative or an analogue thereof | |
KR20080035594A (ko) | 크산틴옥시다아제 저해제 | |
HU197749B (en) | Process for producing /3,4-d/pyrimidine derivatives and pharmaceutical compositions comprising these compounds as active ingredient | |
JP6633246B2 (ja) | ヒトpde1阻害薬として有用なトリアゾロピラジノン誘導体 | |
AU2006281359B2 (en) | Condensed pyrimidine derivatives as inhibitors of folic acid-dependent enzymes | |
CS241476B2 (en) | Method of substituted n-5-tetrazolyl-1-oxo-1h-thiazolo- (3,2-a )pyrimidine-2-carboxamides production | |
KR101122376B1 (ko) | 신규의 5,6-다이메틸피리미딘 유도체 및 그의 제조방법 | |
HU202528B (en) | Process for producing pyrimido(2,1-a)isoquinoline derivatives and pharmaceutical compositions comprising same | |
KR101191071B1 (ko) | 축합 피리미딘 유도체 및 크산틴 옥시다제 저해제 | |
JP3059572B2 (ja) | ピロロ[3,2−e]ピラゾロ[1,5−a]ピリミジン誘導体及びこれを有効成分とする高血圧治療剤 | |
JPH0558434B2 (ko) | ||
JP2002241369A (ja) | 4−ピリミジニルアミノアセトアミド誘導体及びそれを含有する医薬組成物 | |
JPH03279378A (ja) | ベンゾピラン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120914 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130913 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140912 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150911 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160909 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170908 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190916 Year of fee payment: 11 |